Prospective study supports use of 21-gene assay to spare chemotherapy in breast cancer
12. 10. 2015 | ecancer.org
The TAILORx prospective study provides the best evidence yet that a 21 gene assay can identify women with breast cancer who can be spared chemotherapy, reports the New England Journal of Medicine [1].
Image credit: Martin Lopez (pexels.com)
Previous studies have shown the 21-gene expression assay, produced by Oncotype DX, can provide additional prognostic information independent of clinicopathologic features and predict benefit from adjuvant chemotherapy in oestrogen-receptor-positive disease.
Since validation in prospectively conducted studies provides the highest level of evidence supporting clinical validity, Joseph Sparano and colleagues, from Montefiore Medical Center, New York, undertook the Trial Assigning Individualised Options for Treatment (TAILORx) study.
Read the whole article at ecancer.org
Reference
- Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. New England Journal of Medicine 2015. doi: 10.1056/NEJMoa1510764
Keywords: recurrence score, breast cancer, chemotherapy, 21-gene expression assay
